Stempoint Capital’s Protagonist Therapeutics PTGX Stock Holding History

Stempoint Capital’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2M	Sell	16,303 -56,274	-78%	-$5.88M	0.34%	64
2026 Q1	$7.65M	Buy	72,577 +13,147	+22%	+$1.16M	1.46%	25
2025 Q4	$5.19M	Buy	59,430 +11,476	+24%	+$939K	0.89%	38
2025 Q3	$3.19M	Buy	47,954 +31,184	+186%	+$1.77M	0.64%	38
2025 Q2	$927K	Sell	16,770 -32,471	-66%	-$1.56M	0.3%	45
2025 Q1	$2.38M	Sell	49,241 -92,473	-65%	-$3.87M	0.76%	30
2024 Q4	$5.47M	Buy	+141,714	New	+$6.18M	1.37%	26
2024 Q1	–	Sell	-513,681	Closed	-$11.8M	–	89
2023 Q4	$11.8M	Buy	+513,681	New	+$8.99M	3.14%	7

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Stempoint Capital's PTGX Position: Q2 2026 in Review

Stempoint Capital reduced its Protagonist Therapeutics (PTGX) stake by 78% in Q2 2026, selling an estimated $5.88M and leaving 16,303 shares worth $2M. The position accounts for 0.34% of the portfolio, ranked #64.

Stempoint Capital first reported a position in PTGX in Q4 2023 and has held it in 8 quarters since. The position peaked at $11.8M in Q4 2023. 343 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

Stempoint Capital held 16,303 shares of Protagonist Therapeutics worth $2M as of Q2 2026.
Stempoint Capital sold 56,274 Protagonist Therapeutics shares in Q2 2026, an estimated $5.88M.
Protagonist Therapeutics made up 0.34% of Stempoint Capital's portfolio in Q2 2026, its #64 holding.
Stempoint Capital first reported a position in Protagonist Therapeutics in Q4 2023 and has held it in 8 quarters since.
Stempoint Capital's Protagonist Therapeutics position peaked at $11.8M in Q4 2023.
343 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Stempoint Capital's 13F filing for Q2 2026, filed 14 Aug 2026.